Journal of Clinical Oncology
Articles in this Issue
A propensity score–matched real-world analysis of immune checkpoint inhibitors in melanoma patients with autoimmune disease.
9594 Background: Immune checkpoint inhibitors (ICIs) are foundational in the treatment of melanoma. However, patients with...
Changes in the incidence of second malignant neoplasms in neuroblastoma over time: An updated SEER database analysis.
10040 Background: To investigate changes in the incidence of second malignant neoplasms (SMN) for patients with neuroblast...
Real-world impact of metabolic, renal, and demographic factors on overall survival in well- to moderately differentiated gastrointestinal and pancreatic neuroendocrine tumors.
e16326 Background: Well- to moderately differentiated gastrointestinal and pancreatic neuroendocrine tumors (NETs) show su...
Impact of first-line <i>EGFR</i> TKI dose reduction on survival and treatment sequencing in metastatic <i>EGFR</i> -mutant non–small cell lung cancer: A real-world cohort study.
e20746 Background: Dose reduction during first-line EGFR tyrosine kinase inhibitor...
Genomic landscape of <i>ERBB3</i> alterations in 5,416 metastatic solid tumors: Real-world evidence regarding biomarker-agnostic ADC strategies.
3090 Background: While ERBB2 (HER2) is a well-established therapeutic target, the clinical significance and genomic landsc...
ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
TPS7100 Background: Bruton tyrosine kinase covalent inhibitors (cBTKi) have been transformative in CLL treatment. Despite...
Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.
11567 Background: TGCT is a rare, locally-aggressive, soft-tissue tumor driven by colony-stimulating factor-1 (CSF-1) over...
Heterogeneity in biomarkers for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) across regions: Insights from CheckMate-649.
4056 Background: In CheckMate 649, first-line nivolumab plus chemotherapy showed improved clinical efficacy vs chemotherap...
Telehealth visits to support extended dosing of pembrolizumab and reduce health care visits: A pragmatic trial.
1515 Background: Single agent pembrolizumab is standardly administered every 3 weeks (q3wk). Although extended interval do...
Real-world comparative outcomes of including levetiracetam with standard treatment in glioblastoma multiforme: A multi-center retrospective cohort study.
e14055 Background: Despite standard therapy temozolamide (TMZ), overall survival in Glioblastoma multiforme (GBM) remains...
Impact of body mass index on toxicity and outcomes after CD19-directed CAR-T therapy for non-Hodgkin lymphoma.
e19072 Background: CAR-T therapy has improved outcomes for patients with R/R B-cell lymphomas; however, in overweight and...
Real-world adoption of comprehensive genomic profiling in a national cohort of patients with resected stage I–III non–small cell lung cancer.
8043 Background: Comprehensive genomic profiling (CGP) is increasingly used in the multidisciplinary management of resecta...
Retrospective analysis of colorectal cancer mutations and their associated risk of oxaliplatin-induced peripheral neuropathy.
e24091 Background: Oxaliplatin-induced peripheral neuropathy (OIPN) presents a huge clinical challenge for patients and cl...
Rab11 family interacting proteins as regulators of T cell recognition and infiltration in triple negative breast cancer.
2555 Background: Triple negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases and has the worst pro...
Long-term survival and biomarker analysis of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.
3610 Background: We previously reported that adding sintilimab to neoadjuvant chemoradiotherapy (NACRT) significantly impr...
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor–positive, HER-2–negative metastatic breast cancer: A real-world, multicenter, retrospective study.
e24144 Background: In metastatic hormone receptor (HR)-positive and HER-2-negative breast cancer, toxicity with CDK 4/6 in...
Sepsis-related mortality in adults with liver and intrahepatic bile duct malignancies: A 25-year national analysis of trends and disparities, 1999-2023.
e16204 Background: Sepsis is a frequent and often terminal complication in patients with malignant neoplasms of the liver...
A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
5506 Background: Mirvetuximab soravtansine (MIRV) has demonstrated single agent activity in patients with platinum-resista...
Trends and disparities in lung cancer and hypertension-related mortality in the United States, 1999–2023.
e23366 Background: Lung cancer remains a primary driver of mortality in the United States, frequently occurring alongside...
Pathologic complete response and association with survival benefit in hormone receptor–positive breast cancer BRCA carriers.
e12670 Background: In hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) breast can...
Epidemiological trends and burden of thyroid cancer mortality in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.
e18126 Background: Thyroid cancer mortality shows regional heterogeneity, with rising trends in many low- and middle-incom...
Elderly patients with extranodal MZL: Academic vs community care outcomes.
e13610 Background: Extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue (MALT lymphoma) is the mo...
Consolidated PD-L1 inhibitors after chemoradiotherapy versus placebo in non-resectable non–small cell lung carcinoma: A meta-analysis of phase III randomized controlled trials.
e20075 Background: The PACIFIC trial established the use of durvalumab, an immune-checkpoint inhibitor (ICI), following co...
Implementation of serum microRNA-371a-3p testing for testicular germ-cell tumors in a pathology department: Real-world data from a comprehensive cancer center.
5025 Background: The classical serum tumor markers for testicular germ cell tumor (TGCT) patients show limited sensitivity...
Comparison of CLDN18/CLDN18.2 IHC assays (43-14A vs EPR19202) and the correlation with clinical efficacy in patients with gastric/gastroesophageal junction adenocarcinoma treated by the novel antibody-drug conjugate XNW27011.
4061 Background: Claudin 18.2 (CLDN18.2), the dominant isoform of CLDN18 in gastric tissues, is a highly specific tight ju...